| Ytd | -61.90% | |
| 1y | -55.91% |
| Open | 4.86 | Prev Close | 4.89 | Low | 4.69 | High | 4.86 | Mkt Cap | 382.43M |
| Vol | 1.23M | Avg Vol | 438.38K | EPS | -2.27 | P/E | N/A | Forward P/E | N/A |
| Beta | 0.38 | Short Ratio | 4.43 | Inst. Own | 52.88% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 11-11 | 50-d Avg | 8.35 | 200-d Avg | 9.51 | 1yr Est | 24.20 |
BBOT News
BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) has been assigned a consensus
Gainers Tenon Medical (NASDAQ:TNON) stock moved upwards by 76.4% to $4.3 during Thursday's regu
Leerink Partners analyst Andrew Berens maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperfo
Canaccord Genuity analyst John Newman maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and l
Raymond James analyst Sean McCutcheon maintains BridgeBio Oncology (NASDAQ:BBOT) with a Outperfor
Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regula
Stifel analyst Laura Prendergast maintains BridgeBio Oncology (NASDAQ:BBOT) with a Buy and lowers
Wedbush analyst David Nierengarten reiterates BridgeBio Oncology (NASDAQ:BBOT) with a Outperform
BBO-8520 plus pembrolizumab demonstrated a 75% ORR at 500 mg QD and 53% ORR across dose levels in 2L
SOUTH SAN FRANCISCO, Calif., Sept. 08, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc
SOUTH SAN FRANCISCO, Calif., Sept. 01, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight an
SOUTH SAN FRANCISCO, Calif., Aug. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(705.20) per share which missed the a
Continued to advance monotherapy and combination cohorts for all clinical programs Initiated dosing
Shares of BridgeBio Oncology Therapeutics, Inc (NASDAQ: BBOT - Get Free Report) have earned an avera
BridgeBio Oncology Therapeutics remains a Buy, despite a >30% decline since prior coverage, supporte
U.S. stocks fell, Nasdaq down 100 points. Penguin Solutions Inc (PENG) rose 18.8% after better-than-
JP Morgan analyst Priyanka Grover initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a O
Oppenheimer analyst Mazahir Alimohamed assumes BridgeBio Oncology (NASDAQ:BBOT) with a Outperform
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(526.11).This is a 870.15 percent dec
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., May 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.,
Top Wall Street analysts changed outlook on top names. For full rating changes, check analyst rating
Pre-Market Stock Futures: Futures are trading mixed as we get set to start the new trading week, as
Canaccord Genuity analyst John Newman initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut
BBO-11818 targets KRAS in both its ON (active GTP-bound) and OFF (inactive GDP-bound) states, potent
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (Nasdaq: BBOT), a clinical-stage biopharmaceu
Pedro J. Beltran, PhD, a seasoned executive who previously served as Chief Scientific Officer of BBO
BridgeBio Oncology Therapeutics, Inc. ("BBOT") (NASDAQ:BBOT), a clinical-stage biopharmaceut
BBO-10203 physically and allosterically disrupts the interaction between RAS and PI3Kα, leading to s
BridgeBio Oncology Therapeutics is advancing differentiated KRAS inhibitors, targeting both active a
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv
BBO-11818 is currently being evaluated in the Phase 1 KONQUER-101 trial in subjects with locally adv
SOUTH SAN FRANCISCO, Calif., March 18, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O
BBO-11818 is a selective, orally bioavailable non-covalent inhibitor that targets KRAS in both the O
HC Wainwright & Co. analyst Robert Burns maintains BridgeBio Oncology (NASDAQ:BBOT) with a Bu
BridgeBio Oncology (NASDAQ:BBOT) reported quarterly losses of $(0.49) per share which beat the analy
BBOT debuted as a publicly traded oncology company developing a differentiated portfolio of three cl
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
SOUTH SAN FRANCISCO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- BridgeBio Oncology Therapeutics, Inc.
Stifel analyst Laura Prendergast initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with a Bu
Raymond James analyst Sean McCutcheon initiates coverage on BridgeBio Oncology (NASDAQ:BBOT) with